mca2389b Search Results


anti ly6c  (Bio-Rad)
96
Bio-Rad anti ly6c
Anti Ly6c, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mca2389b/pmc07988765-241-43-46?v=Bio-Rad
Average 96 stars, based on 1 article reviews
anti ly6c - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
anti mouse ly6c  (Bio-Rad)
93
Bio-Rad anti mouse ly6c
Reduced graft‐versus‐host disease (GvHD) lethality in mice treated with small interfering RNA (siRNA) against CD40. (A) Experimental protocol of allogenic bone marrow transplantation (BMT): all mice received 8 Gy total body irradiation. In the allogeneic BMT group, F1 mice were given B6 donor splenocytes and BM cells. F1 mice received F1 splenocytes and BM cells to establish the syngeneic BMT group. Allogenic BMT mice were treated either with/without siRNA targeting mouse CD40 (siCD40/schizophyllan [SPG]) called NJA‐312, NJA‐302, or NJA‐515. (B) Splenocytes retrieved at day 34 after BMT were co‐stained with antibodies against Dectin1, CD40, and <t>Ly6c.</t> Percentages of Dectin+ and Dectin+CD11c‐ cells were determined by three‐color flourescence‐activated cell sorting (FACS) in splenocytes from mice receiving 8 Gy (irradiation, n = 2) without BMT (noBMT, 8 Gy, n = 3). (C) Splenocytes retrieved at indicated time points and treatment groups (after NJA‐312, NJA‐302, and NJA‐515 treatment) were analyzed by FACS using the following antibodies: anti‐Dectin1, anti‐Ly6c, and anti‐CD40 ( n = 1–2/group). (D) Survival of mice undergoing indicated treatments was monitored daily. Data were plotted as a Kaplan–Meier curve. Statistics using SPSS software using log‐rank (Mantel‐Cox). Left panel: indicated groups are shown (same data as left panel). The number of mice per group were as follows: *NJA‐312low ( n = 11); >80 d irradiation ( n = 12); >80 syngeneic BMT ( n = 10); d73 NJA‐302 ( n = 14); d73 NJA‐515 ( n = 15); d73 NJA‐312high ( n = 13); d34 allog BMT ( n = 25). (E) Bodyweight was determined weekly ( n = 7 per treatment group). Left panel: all groups are shown. Right panel: only indicated groups are shown (same data as left panel). * p < 0.05; ** p < 0.01, *** p < 0.0001
Anti Mouse Ly6c, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mca2389b/pmc09421973-43-14-16?v=Bio-Rad
Average 93 stars, based on 1 article reviews
anti mouse ly6c - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
f4 80  (Bio-Rad)
96
Bio-Rad f4 80
Reduced graft‐versus‐host disease (GvHD) lethality in mice treated with small interfering RNA (siRNA) against CD40. (A) Experimental protocol of allogenic bone marrow transplantation (BMT): all mice received 8 Gy total body irradiation. In the allogeneic BMT group, F1 mice were given B6 donor splenocytes and BM cells. F1 mice received F1 splenocytes and BM cells to establish the syngeneic BMT group. Allogenic BMT mice were treated either with/without siRNA targeting mouse CD40 (siCD40/schizophyllan [SPG]) called NJA‐312, NJA‐302, or NJA‐515. (B) Splenocytes retrieved at day 34 after BMT were co‐stained with antibodies against Dectin1, CD40, and <t>Ly6c.</t> Percentages of Dectin+ and Dectin+CD11c‐ cells were determined by three‐color flourescence‐activated cell sorting (FACS) in splenocytes from mice receiving 8 Gy (irradiation, n = 2) without BMT (noBMT, 8 Gy, n = 3). (C) Splenocytes retrieved at indicated time points and treatment groups (after NJA‐312, NJA‐302, and NJA‐515 treatment) were analyzed by FACS using the following antibodies: anti‐Dectin1, anti‐Ly6c, and anti‐CD40 ( n = 1–2/group). (D) Survival of mice undergoing indicated treatments was monitored daily. Data were plotted as a Kaplan–Meier curve. Statistics using SPSS software using log‐rank (Mantel‐Cox). Left panel: indicated groups are shown (same data as left panel). The number of mice per group were as follows: *NJA‐312low ( n = 11); >80 d irradiation ( n = 12); >80 syngeneic BMT ( n = 10); d73 NJA‐302 ( n = 14); d73 NJA‐515 ( n = 15); d73 NJA‐312high ( n = 13); d34 allog BMT ( n = 25). (E) Bodyweight was determined weekly ( n = 7 per treatment group). Left panel: all groups are shown. Right panel: only indicated groups are shown (same data as left panel). * p < 0.05; ** p < 0.01, *** p < 0.0001
F4 80, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mca2389b/pmc04382317-82-49-51?v=Bio-Rad
Average 96 stars, based on 1 article reviews
f4 80 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

Image Search Results


Reduced graft‐versus‐host disease (GvHD) lethality in mice treated with small interfering RNA (siRNA) against CD40. (A) Experimental protocol of allogenic bone marrow transplantation (BMT): all mice received 8 Gy total body irradiation. In the allogeneic BMT group, F1 mice were given B6 donor splenocytes and BM cells. F1 mice received F1 splenocytes and BM cells to establish the syngeneic BMT group. Allogenic BMT mice were treated either with/without siRNA targeting mouse CD40 (siCD40/schizophyllan [SPG]) called NJA‐312, NJA‐302, or NJA‐515. (B) Splenocytes retrieved at day 34 after BMT were co‐stained with antibodies against Dectin1, CD40, and Ly6c. Percentages of Dectin+ and Dectin+CD11c‐ cells were determined by three‐color flourescence‐activated cell sorting (FACS) in splenocytes from mice receiving 8 Gy (irradiation, n = 2) without BMT (noBMT, 8 Gy, n = 3). (C) Splenocytes retrieved at indicated time points and treatment groups (after NJA‐312, NJA‐302, and NJA‐515 treatment) were analyzed by FACS using the following antibodies: anti‐Dectin1, anti‐Ly6c, and anti‐CD40 ( n = 1–2/group). (D) Survival of mice undergoing indicated treatments was monitored daily. Data were plotted as a Kaplan–Meier curve. Statistics using SPSS software using log‐rank (Mantel‐Cox). Left panel: indicated groups are shown (same data as left panel). The number of mice per group were as follows: *NJA‐312low ( n = 11); >80 d irradiation ( n = 12); >80 syngeneic BMT ( n = 10); d73 NJA‐302 ( n = 14); d73 NJA‐515 ( n = 15); d73 NJA‐312high ( n = 13); d34 allog BMT ( n = 25). (E) Bodyweight was determined weekly ( n = 7 per treatment group). Left panel: all groups are shown. Right panel: only indicated groups are shown (same data as left panel). * p < 0.05; ** p < 0.01, *** p < 0.0001

Journal: EJHaem

Article Title: siRNA against CD40 delivered via a fungal recognition receptor ameliorates murine acute graft‐versus‐host disease

doi: 10.1002/jha2.439

Figure Lengend Snippet: Reduced graft‐versus‐host disease (GvHD) lethality in mice treated with small interfering RNA (siRNA) against CD40. (A) Experimental protocol of allogenic bone marrow transplantation (BMT): all mice received 8 Gy total body irradiation. In the allogeneic BMT group, F1 mice were given B6 donor splenocytes and BM cells. F1 mice received F1 splenocytes and BM cells to establish the syngeneic BMT group. Allogenic BMT mice were treated either with/without siRNA targeting mouse CD40 (siCD40/schizophyllan [SPG]) called NJA‐312, NJA‐302, or NJA‐515. (B) Splenocytes retrieved at day 34 after BMT were co‐stained with antibodies against Dectin1, CD40, and Ly6c. Percentages of Dectin+ and Dectin+CD11c‐ cells were determined by three‐color flourescence‐activated cell sorting (FACS) in splenocytes from mice receiving 8 Gy (irradiation, n = 2) without BMT (noBMT, 8 Gy, n = 3). (C) Splenocytes retrieved at indicated time points and treatment groups (after NJA‐312, NJA‐302, and NJA‐515 treatment) were analyzed by FACS using the following antibodies: anti‐Dectin1, anti‐Ly6c, and anti‐CD40 ( n = 1–2/group). (D) Survival of mice undergoing indicated treatments was monitored daily. Data were plotted as a Kaplan–Meier curve. Statistics using SPSS software using log‐rank (Mantel‐Cox). Left panel: indicated groups are shown (same data as left panel). The number of mice per group were as follows: *NJA‐312low ( n = 11); >80 d irradiation ( n = 12); >80 syngeneic BMT ( n = 10); d73 NJA‐302 ( n = 14); d73 NJA‐515 ( n = 15); d73 NJA‐312high ( n = 13); d34 allog BMT ( n = 25). (E) Bodyweight was determined weekly ( n = 7 per treatment group). Left panel: all groups are shown. Right panel: only indicated groups are shown (same data as left panel). * p < 0.05; ** p < 0.01, *** p < 0.0001

Article Snippet: Cells (1 × 10 6 ) were stained with Fluorescein isothiocyanate Fluorescein isothiocyanate (FITC)‐conjugated anti‐mouse Ly6c (AbD Serotec, Duesseldorf, Germany), FITC‐conjugated H2kd, Phycoerythrin (PE)‐conjugated anti‐H2kb, PE‐conjugated anti‐CD40, PE‐conjugated anti‐CD4, FITC‐conjugated anti‐CD8a, APC‐conjugated anti‐B‐220, APC‐conjugated anti‐CD369 (PharMingen, San Diego, CA, USA), and APC‐conjugated CD3e and analyzed on a FACSCalibur.

Techniques: Small Interfering RNA, Transplantation Assay, Irradiation, Staining, FACS, Software